DAFTAR PUSTAKA

1. Depkes, Pedoman Tata Laksana Penyakit Jantung. Jakarta. Ditjen POM.2006 Dalam www.depkesindo.go.id. diakses tanggal 10 Oktober 2013

2. Al-Assaf, Mutu Pelayanan Kesehatan. Jakarta. Salemba;2009.hal: 26-27

3. Sofian, Prevalensi jantung koroner di dunia. 2012 Dalam www. repository.usu.ac.id diakses tanggal 15 Oktober 2013

4. Kemenkes, Angka kejadian jantung koroner di Indonesia.2010 Dalam www.depkes.go.id. diakses tanggal 17 Oktober 2013

5. Lindahl.B,Cardiac Troponin for Risk Assesment and Management of Non-ST-Elevation Acut Coronary Syndrome. Dalam: Cardiovascular Biomarker: Pathophysiology abd Disease management. Edisi David A Morrow Humana Press inc.Totowa,New Jersey, 2006. hal:79-92

6. Nur, Samsu, Sensitivitas dan Spesifisitas CKMB dan Troponin pada Diagnosis Infrak Miokard Akut, 2007.hal: 35-40

7. Guyton AC, Hall JE. Buku Ajar Fisiologi Kedokteran. Edisi 11 Penerbit Buku Kedokteran EGC.2006.Hal: 107

8. Wibowo DS, Paryana Y, Anatomi Tubuh Manusia. Penerbit Graha Ilmu. 2007. Hal:228-235

9. Aaronson PI, Ward JPT, At a Glance Cardiovascular System. Edisi 3 Penerbit Buku Erlangga. 2010. Hal:90-93

10. Achar SA, Kundu S, Norcross WA. Diagnosis of Acute Coronary Syndrome.dalam: American Family Physician 2005;72: 119-26

11. Adam JE. Emerging Biomarker of Myocardial Ischemia. Dalam: Cardiovascular Biomarker: Pathophysiology and Disease Management. Edisi David A Morrow Humana Press inc.Totowa,New Jersey, 2006. hal:191-201

12. Christenson RH. Azzazy HME. Biomarker of Myocardial Necrosis. Dalam: Cardiovascular Biomarker: Pathophysiology and Disease Management. Edisi David A Morrow Humana Press inc.Totowa,New Jersey, 2006. hal: 3-22

13. Jaffe AS, babulin L. Defining Myocardial Infraction. Dalam: Cardiovascular Biomarker: Pathophysiology and Disease Management. Edisi David A Morrow Humana Press inc.Totowa,New Jersey, 2006. hal: 41-53

14. Heeschen C. Beyond C-Reactive Protein. Dalam: Cardiovascular Biomarker: Pathophysiology and Disease Management. Edisi David A Morrow Humana Press inc.Totowa,New Jersey, 2006. hal: 277-90

15. Roche Diagnostis. Manual Methode Cobas Enzyme CKMB. Cobas 6000

16. Groot MJ, Wodzig KW, Simons ML, Glatz JF, Herment WT, Measurement of myocardial infarc size from plasma fatty acid binding protein or myoglobin, using individually estimed clearance rates. Cardiovasculer Research, 1999. 44: 315 – 324.

17. Glatz JF, Kleine AH, Nieuwenhoven FA, Hermens WT, Dieijen MO, Vusse GJ, Fatty acid binding protein as a plasma marker for the estimation of myocardial infarc size in human. Heart, 1994. 71: 135-140

18. Alhadi HA, Fox KA, Do we need additional marker of myocyte necrosis: the potensial value of heart fatty acid binding protein. QJMed, 2004. 97: 187-198.

19. Anonymous, 2008. Human cardiac utility of heart type fatty acid binding protein (HFABP) ELISA tes kit. Available from: www. Oxisresearch com.

20. RAMP Point of Care Diagnostics for Cardiac Markers. Response Biomedical Corporation 2007

21. Binas B, Danneberg H, Whir J, Mullins L, Clark AJ, Requirement for the heart – fatty acid binding protein in cardiac fatty acid utilization. FASEB J, 1999. 13: 805-812.

22. Ghani F, Allan HB, Graff L, Petry C, Armstrong G, Prigent et al, Role of heart fatty acid binding protein in early detection of acute myocardial infarction. Clien Chem, 2000.46 (4):718-719

23. Okamoto F, Sohmiya K, Kawamura K, Asayama K, Kimura H, Nishimura S et al, Human heart type cytoplasmic fatty acid binding protein (HFABP)for the diagnostic of acute myocard infarction. Clinical evaluation of HFABP in comparison with myoglobin and creatin kinase isoenzim MB. Clin Chem. Lab Med. 2000. 38 (3) : 231-238

24. Siswanto, Susila, Suyanto, Metodologi Penelitian Kesehatan dan Kedokteran. Penerbit Bursa Ilmu.2013. hal:234-26

25. Notoatmodjo, Soekidjo. Metodologi Penelitian Kesehatan. Jakarta. Rineka Cipta. 2005.